NR3C2 and Anxiety: The finding that treatment with the mineralocorticoid receptor antagonist (MRA) spironolactone significantly predicted lower anxiety after 12 months in the male subgroup is partly consistent with findings of previous studies suggesting an anxiolytic effect of MRAs and an anxiogenic effect of aldosterone.